Atherosclerosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Atherosclerosis Market Outlook
Thelansis’s “Atherosclerosis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Atherosclerosis treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Atherosclerosis
Overview
Atherosclerosis,
a chronic inflammatory condition marked by plaque buildup in arteries, is a
leading cause of atherosclerotic cardiovascular disease (ASCVD). These plaques,
predominantly lipid-based, trigger inflammation, disrupting blood flow. ASCVD
results from various factors, including high LDL cholesterol, hypertension,
diabetes, smoking, age (typically over 45 for males, 55 for females), gender
(male), and family history of cardiovascular disease. The progression of
atherosclerosis primarily involves the continual formation of arterial wall
lesions due to lipid retention within the intima, facilitated by substances
like proteoglycans. This process exacerbates chronic inflammation at vulnerable
arterial sites, significantly affecting atherogenic progression at all stages.
Angiography is the main method for imaging atherosclerotic lesions in the
coronary circulation, providing crucial insights into coronary morphology.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment